The NHS is set to provide a groundbreaking therapy, stereotactic radiotherapy (SABR), for prostate cancer patients, significantly improving treatment efficiency. This innovative technique reduces the number of necessary treatment sessions from 20 to just five, allowing for higher doses of radiation delivered from multiple angles. NHS England plans to implement this therapy across all 48 radiotherapy centers in England within three months, with some centers beginning as early as next week. Approximately 17,500 men are diagnosed with low or intermediate risk prostate cancer annually in England, and modeling suggests that around 3,500 could opt for this new treatment. The therapy not only minimizes side effects but also alleviates the burden of frequent hospital visits, potentially freeing up 50,000 appointments each year. Experts, including NHS chief executive Sir Jim Mackey, emphasize that this approach will transform care for prostate cancer patients, allowing them to return to their daily lives more quickly. Prostate Cancer UK and other organizations are advocating for rapid deployment of this treatment to ensure equitable access across the country.